Efficacy and safety of trabectedin in patients with advanced or ...

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated ...

According to Response Evaluation Criteria in Solid Tumors (RECIST), after a median follow-up of 14·0 months (IQR 8·7–20·0), two patients had ...

NCT01343277 - Cancer Trial Results

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy ...

Safety and efficacy of trabectedin when administered in the inpatient ...

Conclusions: Although the majority of patients who were randomized to trabectedin received outpatient therapy, the outcomes of the current study ...

Trabectedin for Patients with Advanced Soft Tissue Sarcoma - MDPI

In our study, trabectedin demonstrated a favorable safety profile over long-term treatment, as >40% of patients received ≥6 cycles of trabectedin and up to a ...

Adult Soft Tissue Sarcoma Latest Advances - MediFind

Conclusion: The outcomes of this study suggested similar safety and effectiveness of trabectedin in patients with advanced leiomyosarcoma/ ...

A comprehensive review of the current evidence for trabectedin in ...

It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been ...

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma

locally advanced. (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy. (87.4 months) compared with ...

Efficacy and Safety of Trabectedin (Yondelis®) in Patients With ...

Trabectedin is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who ...

Results of a phase III randomized multicenter clinical trial – Fingerprint

Dive into the research topics of 'Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional ...

Efficacy of Trabectedin in Patients with Advanced or Metastatic ...

Results: In 6 patients with documented disease progression, disease stabilization was reached with trabectedin; only 1 patient experienced ...

Trabectedin plus Durvalumab in Patients with Advanced Pretreated ...

This is the first full report of a study investigating the combination of trabectedin with an immune checkpoint inhibitor in solid tumors. In this study of ...

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo

Median number of trabectedin cycles was 3 (range, 1–17). About 69/72 patients (95.8%) were evaluable for response: 9 patients (13%) achieved ...

Trabectedin is a feasible treatment for soft tissue sarcoma patients ...

... efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS). Data from 350 adults ...

Trabectedin for Soft Tissue Sarcoma: Current Status and Future ...

In the US, trabectedin (Yondelis,) gained FDA approval on 23 October 2015 for unresectable or metastatic liposarcoma or leiomyosarcoma patients ...

Retrospective Analysis of Trabectedin Therapy for Soft Tissue ...

The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS. Patients and Methods: We ...

or later-line treatment of patients with advanced soft tissue sarcoma ...

The only treatment that demonstrated a similar anti-tumour activity across different trials was trabectedin (three studies). Trabectedin was ...

Safety Profile - YONDELIS®

YONDELIS® (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior ...

The Role of Trabectedin in Soft Tissue Sarcoma - Frontiers

Results: Trabectedin can be administered safely and effectively to the patients with advanced STS at second line setting or later. Although ...

10-Year Trabectedin Real-World Data Demonstrate Efficacy in ...

... clinical benefit rate for patients with advanced high grade soft ... “Trabectedin is a safe and effective drug in advanced high-grade STS.

Trabectedin (Yondelis) - Medical Clinical Policy Bulletins - Aetna

Recently, a randomized phase II clinical trial in patients with translocation-related sarcomas unresponsive or intolerable to standard chemotherapy was ...